

Tine W Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8269915/publications.pdf>

Version: 2024-02-01

200
papers

14,582
citations

38660

50
h-index

19690

117
g-index

205
all docs

205
docs citations

205
times ranked

14633
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: â€ establishing normal and reference valuesâ€™. <i>European Heart Journal</i> , 2010, 31, 2338-2350.	1.0	1,637
2	Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 636-646.	1.2	1,446
3	Prognostic Value of Aortic Pulse Wave Velocity as Index of Arterial Stiffness in the General Population. <i>Circulation</i> , 2006, 113, 664-670.	1.6	1,308
4	Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. <i>Lancet</i> , The, 2007, 370, 1219-1229.	6.3	766
5	Predictive Role of the Nighttime Blood Pressure. <i>Hypertension</i> , 2011, 57, 3-10.	1.3	482
6	Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations. <i>Hypertension</i> , 2010, 55, 1049-1057.	1.3	394
7	Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. <i>Journal of Hypertension</i> , 2007, 25, 1554-1564.	0.3	328
8	Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. <i>Journal of Internal Medicine</i> , 2010, 268, 296-308.	2.7	327
9	Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. <i>Journal of Hypertension</i> , 2010, 28, 2036-2045.	0.3	318
10	Ambulatory Blood Pressure and Mortality. <i>Hypertension</i> , 2005, 45, 499-504.	1.3	281
11	Diagnostic Thresholds for Ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk. <i>Circulation</i> , 2007, 115, 2145-2152.	1.6	277
12	Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 409.	3.8	265
13	Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations. <i>Hypertension</i> , 2010, 55, 1040-1048.	1.3	258
14	Risk prediction is improved by adding markers of subclinical organ damage to SCORE. <i>European Heart Journal</i> , 2010, 31, 883-891.	1.0	255
15	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 597-609.	5.5	248
16	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2112-2119.	1.2	225
17	Ambulatory Blood Pressure Monitoring and Risk of Cardiovascular Disease: A Population Based Study. <i>American Journal of Hypertension</i> , 2006, 19, 243-250.	1.0	209
18	White-Coat Hypertension. <i>Hypertension</i> , 2013, 62, 982-987.	1.3	185

#	ARTICLE	IF	CITATIONS
19	Significance of White-Coat Hypertension in Older Persons With Isolated Systolic Hypertension. <i>Hypertension</i> , 2012, 59, 564-571.	1.3	177
20	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	5.5	166
21	N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome. <i>Hypertension</i> , 2005, 46, 660-666.	1.3	152
22	Global Changes in Food Supply and the Obesity Epidemic. <i>Current Obesity Reports</i> , 2016, 5, 449-455.	3.5	143
23	Masked Hypertension in Diabetes Mellitus. <i>Hypertension</i> , 2013, 61, 964-971.	1.3	142
24	Setting Thresholds to Varying Blood Pressure Monitoring Intervals Differentially Affects Risk Estimates Associated With White-Coat and Masked Hypertension in the Population. <i>Hypertension</i> , 2014, 64, 935-942.	1.3	137
25	The International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. <i>Blood Pressure Monitoring</i> , 2007, 12, 255-262.	0.4	130
26	Ambulatory arterial stiffness index predicts stroke in a general population. <i>Journal of Hypertension</i> , 2006, 24, 2247-2253.	0.3	129
27	The Cardiovascular Risk of White-Coat Hypertension. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2033-2043.	1.2	129
28	N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. <i>European Heart Journal</i> , 2007, 28, 1374-1381.	1.0	122
29	Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. <i>International Journal of Cardiology</i> , 2013, 167, 2904-2911.	0.8	121
30	Ambulatory Blood Pressure Monitoring in 9357 Subjects From 11 Populations Highlights Missed Opportunities for Cardiovascular Prevention in Women. <i>Hypertension</i> , 2011, 57, 397-405.	1.3	111
31	CRP and suPAR are differently related to anthropometry and subclinical organ damage. <i>International Journal of Cardiology</i> , 2013, 167, 781-785.	0.8	99
32	Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. <i>Journal of Hypertension</i> , 2020, 38, 21-29.	0.3	93
33	Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations. <i>Hypertension</i> , 2008, 52, 229-235.	1.3	87
34	Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations. <i>Circulation</i> , 2014, 130, 466-474.	1.6	84
35	Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. <i>Hypertension Research</i> , 2010, 33, 757-766.	1.5	80
36	Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. <i>Atherosclerosis</i> , 2011, 216, 237-243.	0.4	79

#	ARTICLE	IF	CITATIONS
37	Age-Specific Differences Between Conventional and Ambulatory Daytime Blood Pressure Values. <i>Hypertension</i> , 2014, 64, 1073-1079.	1.3	78
38	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 239-247.	2.2	77
39	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1512-1520.	4.3	77
40	Prognosis in Relation to Blood Pressure Variability. <i>Hypertension</i> , 2015, 65, 1170-1179.	1.3	74
41	Independent prognostic value of the ambulatory arterial stiffness index and aortic pulse wave velocity in a general population. <i>Journal of Human Hypertension</i> , 2008, 22, 214-216.	1.0	69
42	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. <i>Diabetes Care</i> , 2014, 37, 1660-1667.	4.3	68
43	Cardiac ⁸² Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 371-378.	2.9	63
44	Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. <i>Journal of Internal Medicine</i> , 2015, 277, 362-371.	2.7	62
45	Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1088-1094.	4.3	61
46	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. <i>Journal of Hypertension</i> , 2012, 30, 1928-1936.	0.3	60
47	Improved prognosis of diabetic nephropathy in type 1 diabetes. <i>Kidney International</i> , 2015, 87, 417-426.	2.6	58
48	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 670-674.	1.2	58
49	Prevalence, Treatment, and Control Rates of Conventional and Ambulatory Hypertension Across 10 Populations in 3 Continents. <i>Hypertension</i> , 2017, 70, 50-58.	1.3	56
50	Relation between insulin and aortic stiffness: a population-based study. <i>Journal of Human Hypertension</i> , 2004, 18, 1-7.	1.0	51
51	Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: A population-based study. <i>Atherosclerosis</i> , 2006, 189, 369-374.	0.4	51
52	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2018, 41, 1493-1500.	4.3	51
53	How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information?. <i>American Journal of Hypertension</i> , 2014, 27, 46-55.	1.0	49
54	Risk Stratification by Ambulatory Blood Pressure Monitoring Across JNC Classes of Conventional Blood Pressure. <i>American Journal of Hypertension</i> , 2014, 27, 956-965.	1.0	49

#	ARTICLE	IF	CITATIONS
55	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 248-255.	1.2	49
56	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2882-2885.	4.3	49
57	Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 609-618.	1.1	44
58	Cardiovascular Outcome in Relation to Progression to Hypertension in the Copenhagen MONICA Cohort. <i>American Journal of Hypertension</i> , 2007, 20, 483-491.	1.0	41
59	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017, 16, 88.	2.7	41
60	C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 594-598.	3.1	40
61	Outcome-Driven Thresholds for Ambulatory Pulse Pressure in 9938 Participants Recruited From 11 Populations. <i>Hypertension</i> , 2014, 63, 229-237.	1.3	40
62	Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, 2217-2226.	0.3	40
63	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. <i>Journal of Hypertension</i> , 2009, 27, 2351-2357.	0.3	39
64	Blood Pressure Load Does Not Add to Ambulatory Blood Pressure Level for Cardiovascular Risk Stratification. <i>Hypertension</i> , 2014, 63, 925-933.	1.3	39
65	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 901-905.	2.2	39
66	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1112-1119.	4.3	38
67	Determinants of the Ambulatory Arterial Stiffness Index in 7604 Subjects From 6 Populations. <i>Hypertension</i> , 2008, 52, 1038-1044.	1.3	37
68	Double Product Reflects the Predictive Power of Systolic Pressure in the General Population: Evidence from 9,937 Participants. <i>American Journal of Hypertension</i> , 2013, 26, 665-672.	1.0	37
69	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 59.	2.7	35
70	Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta-Analysis—Clinical Implications. <i>Journal of Clinical Hypertension</i> , 2008, 10, 377-381.	1.0	34
71	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017, 18, 52.	0.8	34
72	High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. <i>Journal of Hypertension</i> , 2006, 24, 655-661.	0.3	33

#	ARTICLE	IF	CITATIONS
73	Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. <i>Journal of Hypertension</i> , 2008, 26, 26-34.	0.3	33
74	Opposing Age-Related Trends in Absolute and Relative Risk of Adverse Health Outcomes Associated With Out-of-Office Blood Pressure. <i>Hypertension</i> , 2019, 74, 1333-1342.	1.3	31
75	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013, 12, 122.	2.7	30
76	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1760-1768.	4.3	30
77	Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. <i>Journal of Hypertension</i> , 2009, 27, 1165-1171.	0.3	29
78	Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. <i>Blood Pressure</i> , 2018, 27, 341-350.	0.7	29
79	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. <i>PLoS ONE</i> , 2018, 13, e0196634.	1.1	29
80	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. <i>Hypertension Research</i> , 2011, 34, 714-721.	1.5	28
81	Blood Pressure Variability Remains an Elusive Predictor of Cardiovascular Outcome. <i>American Journal of Hypertension</i> , 2009, 22, 3-4.	1.0	27
82	Measures of overweight and obesity and risk of cardiovascular disease: a population-based study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 486-490.	3.1	27
83	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. <i>Diabetologia</i> , 2020, 63, 2713-2724.	2.9	27
84	Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. <i>Blood Pressure Monitoring</i> , 2007, 12, 393-395.	0.4	26
85	The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. <i>Diabetic Medicine</i> , 2012, 29, 479-487.	1.2	26
86	Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA _{1c} compared with multiple daily injections: a longitudinal follow-up study. <i>Diabetic Medicine</i> , 2015, 32, 1445-1452.	1.2	26
87	Central Hemodynamics Are Associated With Cardiovascular Disease and Albuminuria in Type 1 Diabetes. <i>American Journal of Hypertension</i> , 2014, 27, 1152-1159.	1.0	25
88	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. <i>Diabetologia</i> , 2016, 59, 1549-1557.	2.9	25
89	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017, 92, 1242-1248.	2.6	24
90	Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. <i>Hypertension</i> , 2021, 77, 39-48.	1.3	24

#	ARTICLE	IF	CITATIONS
91	Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). <i>Acta Cardiologica</i> , 2011, 66, 701-706.	0.3	23
92	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018, 55, 1143-1150.	1.2	23
93	Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension. <i>Hypertension</i> , 2019, 74, 776-783.	1.3	23
94	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2016, 65, 3129-3138.	0.3	22
95	Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e017165.	1.6	22
96	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 18522.	1.6	21
97	Reproducibility of the ambulatory arterial stiffness index in hypertensive patients. <i>Journal of Hypertension</i> , 2008, 26, 1993-2000.	0.3	20
98	Cardiovascular Risk Stratification and Blood Pressure Variability on Ambulatory and Home Blood Pressure Measurement. <i>Current Hypertension Reports</i> , 2014, 16, 470.	1.5	20
99	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. <i>PLoS ONE</i> , 2021, 16, e0244402.	1.1	20
100	Is blood pressure during the night more predictive of cardiovascular outcome than during the day?. <i>Blood Pressure Monitoring</i> , 2008, 13, 145-147.	0.4	19
101	Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4181-4188.	1.8	19
102	Covid-19 Effects on ARTERial Stiffness and Vascular Ageing: CARTESIAN Study Rationale and Protocol. <i>Artery Research</i> , 2021, 27, 59.	0.3	19
103	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017, 60, 1883-1891.	2.9	18
104	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012174.	1.3	18
105	Risk Stratification by 24-Hour Ambulatory Blood Pressure and Estimated Glomerular Filtration Rate in 5322 Subjects From 11 Populations. <i>Hypertension</i> , 2013, 61, 18-26.	1.3	17
106	Blood pressure variability in risk stratification: What does it add?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 1-8.	0.9	17
107	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 659-666.	0.4	17
108	Association between albuminuria, atherosclerotic plaques, elevated pulse wave velocity, age, risk category and prognosis in apparently healthy individuals. <i>Journal of Hypertension</i> , 2014, 32, 1034-1041.	0.3	16

#	ARTICLE	IF	CITATIONS
109	Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1596-1604.	1.2	16
110	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 736-740.	2.2	16
111	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 16.	2.7	16
112	Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. <i>Hypertension</i> , 2021, 78, 1222-1231.	1.3	16
113	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. <i>Frontiers in Endocrinology</i> , 2021, 12, 790405.	1.5	16
114	Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. <i>American Journal of Hypertension</i> , 2021, 34, 929-938.	1.0	15
115	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002395.	1.2	14
116	Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes. <i>American Journal of Hypertension</i> , 2015, 28, 772-779.	1.0	13
117	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52.	1.0	13
118	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 162-168.	1.2	13
119	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1277-1286.	0.3	13
120	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 796-803.	0.5	13
121	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020, 15, e0243737.	1.1	13
122	New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. <i>Journal of Human Hypertension</i> , 2009, 23, 105-112.	1.0	12
123	A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. <i>Acta Diabetologica</i> , 2019, 56, 711-712.	1.2	12
124	Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021, 70, 39-50.	0.3	12
125	Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three New Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment?. <i>Current Vascular Pharmacology</i> , 2010, 8, 134-139.	0.8	11
126	Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. <i>American Journal of Hypertension</i> , 2012, 25, 1095-1100.	1.0	11

#	ARTICLE	IF	CITATIONS
127	Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes. <i>Blood Pressure Monitoring</i> , 2013, 18, 156-160.	0.4	11
128	Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. <i>Acta Diabetologica</i> , 2014, 51, 955-962.	1.2	11
129	Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	11
130	Relationship between common lipoprotein lipase gene sequence variants, hyperinsulinemia, and risk of ischemic heart disease: A population-based study. <i>Atherosclerosis</i> , 2010, 211, 506-511.	0.4	10
131	Response to Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus: Attractive But Questionable Interpretations and Response to Is Masked Hypertension Related to Diabetes Mellitus?. <i>Hypertension</i> , 2013, 62, e23-5.	1.3	9
132	Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. <i>Acta Diabetologica</i> , 2014, 51, 973-980.	1.2	9
133	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1261-1265.	2.2	9
134	Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3573.	1.0	9
135	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. <i>Journal of Hypertension</i> , 2012, 30, 513-521.	0.3	8
136	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. <i>Cardiovascular Diabetology</i> , 2016, 15, 67.	2.7	8
137	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 10624.	1.6	8
138	Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy. <i>Scientific Reports</i> , 2021, 11, 15208.	1.6	8
139	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rationale and protocol. <i>Blood Pressure</i> , 2021, 30, 269-281.	0.7	8
140	Tyrosine Hydroxylase Polymorphism (C-824T) and Hypertension: A Population-Based Study. <i>American Journal of Hypertension</i> , 2010, 23, 1306-1311.	1.0	7
141	Risk Associated with Pulse Pressure on Out-of-Office Blood Pressure Measurement. <i>Pulse</i> , 2014, 2, 42-51.	0.9	7
142	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. <i>Cardiovascular Diabetology</i> , 2020, 19, 180.	2.7	7
143	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14459.	1.2	7
144	Starting Antihypertensive Drug Treatment With Combination Therapy. <i>Hypertension</i> , 2021, 77, 788-798.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Urinary peptidome and diabetic retinopathy in the DIRECTâ€Protect 1 and 2 trials. Diabetic Medicine, 2021, 38, e14634.	1.2	7
146	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <scp>LIRAFLAME</scp> randomized <scp>placeboâ€controlled</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	2.2	7
147	Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002289.	1.2	7
148	More Information on the Reproducibility of the Ambulatory Arterial Stiffness Index. American Journal of Hypertension, 2010, 23, 113-114.	1.0	6
149	Cuff inflations do not affect night-time blood pressure. Blood Pressure Monitoring, 2015, 20, 369-372.	0.4	6
150	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1603-1608.	1.2	6
151	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. Journal of Diabetes and Its Complications, 2017, 31, 1164-1168.	1.2	6
152	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2021, 44, 595-603.	4.3	5
153	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	1.3	5
154	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2022, 24, 281-288.	2.2	5
155	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. Nephrology Dialysis Transplantation, 2020, , .	0.4	5
156	From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering's legacy. Blood Pressure Monitoring, 2010, 15, 72-81.	0.4	4
157	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Diabetes Care, 2017, 40, e32-e33.	4.3	4
158	Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. Journal of Diabetes and Its Complications, 2020, 34, 107593.	1.2	4
159	Nonâ€invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. Diabetic Medicine, 2021, 38, e14517.	1.2	4
160	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. Frontiers in Endocrinology, 2021, 12, 780679.	1.5	4
161	Added VALUE of an ancillary study on ambulatory blood pressure monitoring. Journal of Hypertension, 2007, 25, 513-515.	0.3	3
162	1.3 PROGNOSTIC VALUE OF CAROTID-FEMORAL PULSE WAVE VELOCITY FOR CARDIOVASCULAR EVENTS: AN IPD META-ANALYSIS OF PROSPECTIVE OBSERVATIONAL DATA FROM 14 STUDIES INCLUDING 16,358 SUBJECTS. Artery Research, 2011, 5, 138.	0.3	3

#	ARTICLE	IF	CITATIONS
163	Fibrillin-1 genotype and risk of prevalent hypertension: A study in two independent populations. <i>Blood Pressure</i> , 2012, 21, 273-280.	0.7	3
164	Relationship Between Two Common Lipoprotein Lipase Variants and the Metabolic Syndrome and Its Individual Components. <i>Metabolic Syndrome and Related Disorders</i> , 2016, 14, 442-448.	0.5	3
165	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. <i>PLoS ONE</i> , 2021, 16, e0254859.	1.1	3
166	Autonomic nervous system activity in primary Raynaud's phenomenon: Heart rate variability, plasma catecholamines and ¹²³ I-MIBG heart scintigraphy. <i>Clinical Physiology and Functional Imaging</i> , 2022, 42, 104-113.	0.5	3
167	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. <i>Frontiers in Pharmacology</i> , 2022, 13, 799915.	1.6	3
168	Letter Regarding Article by Sega et al, "Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population." <i>Circulation</i> , 2005, 112, e244; author reply e245-6.	1.6	2
169	Ambulatory blood pressure monitoring for risk stratification in obese and non-obese subjects from 10 populations. <i>Journal of Human Hypertension</i> , 2014, 28, 535-542.	1.0	2
170	Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> 2019;42:1088-1094. <i>Diabetes Care</i> , 2019, 42, e188-e188.	4.3	2
171	Spotlights on Ambulatory Measures of Arterial Stiffness. <i>American Journal of Hypertension</i> , 2008, 21, 368-369.	1.0	1
172	Sensor for vascular compliance and blood pressure. , 2009, , .		1
173	Blood Pressure Variability as Elusive Harbinger of Adverse Health Outcomes. , 2016, , 129-148.		1
174	ASSOCIATION OF FATAL AND NONFATAL CARDIOVASCULAR OUTCOMES WITH 24 HOUR MEAN ARTERIAL PRESSURE. <i>Journal of Hypertension</i> , 2021, 39, e88.	0.3	1
175	FC 058 THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
176	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.3	1
177	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1638-1642.	2.2	1
178	Day or night blood pressures for prognosis " Authors' reply. <i>Lancet</i> , The, 2008, 371, 114-115.	6.3	0
179	Response to Determinants of the Ambulatory Arterial Stiffness Index Regression Line. <i>Hypertension</i> , 2009, 53, .	1.3	0
180	Sex-specific relative and absolute risks associated with the conventional and ambulatory blood pressures in 9357 subjects from 11 populations. <i>International Journal of Cardiology</i> , 2009, 137, S21-S22.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Prognostic value of short-term blood pressure variability over 24 h in 8938 subjects from 11 populations. <i>International Journal of Cardiology</i> , 2009, 137, S22.	0.8	0
182	Comments on the reproducibility of ambulatory arterial stiffness index and QRS Korotkoff delay index. <i>Journal of Hypertension</i> , 2009, 27, 436-437.	0.3	0
183	Response to Indices of Blood Pressure Variability and Cardiovascular Risk. <i>Hypertension</i> , 2010, 56, .	1.3	0
184	Response to Referral of Women to Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2011, 57, .	1.3	0
185	White-coat Hypertension on Automated Blood Pressure Measurement: Implications for Clinical Practice. <i>The European Journal of Cardiovascular Medicine</i> , 2011, , .	1.0	0
186	P3.3 CARDIAC 82RB-PET/CT REVEALS MICROVASCULAR DYSFUNCTION IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES. <i>Artery Research</i> , 2014, 8, 137.	0.3	0
187	P153 MARKER OF TYPE VI COLLAGEN FORMATION (PRO-C6) IS ASSOCIATED WITH HIGHER ARTERIAL STIFFNESS IN TYPE 1 DIABETES. <i>Artery Research</i> , 2017, 20, 103.	0.3	0
188	3.7 PULSE WAVE VELOCITY IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS, MORTALITY AND DECLINE IN RENAL FUNCTION IN PATIENTS WITH TYPE 1 DIABETES. <i>Artery Research</i> , 2018, 24, 74.	0.3	0
189	A3993 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes. <i>Journal of Hypertension</i> , 2018, 36, e147.	0.3	0
190	A18355 Age- sex- and ethnicity-specific prediction of cardiovascular outcomes by in-office and out-of-the-office blood pressure. <i>Journal of Hypertension</i> , 2018, 36, e310-e311.	0.3	0
191	A18029 Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New ACC/AHA Classification of Hypertension. <i>Journal of Hypertension</i> , 2018, 36, e345.	0.3	0
192	A17393 Systolic and diastolic nocturnal blood pressure dipping differentially predict adverse health outcomes in 8857 untreated participants from 12 populations. <i>Journal of Hypertension</i> , 2018, 36, e341.	0.3	0
193	SP418COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i488-i488.	0.4	0
194	PREDICTIVE POWER OF 24-HOUR AMBULATORY PULSE PRESSURE AND ITS COMPONENTS FOR MORTALITY AND CARDIOVASCULAR OUTCOMES IN 11,848 PARTICIPANTS RECRUITED FROM 13 POPULATIONS. <i>Journal of Hypertension</i> , 2021, 39, e3-e4.	0.3	0
195	380-P: Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, .	0.3	0
196	430-P: Urinary Proteome and Diabetic Retinopathy in the Direct-Protect 1 and 2 Trials. <i>Diabetes</i> , 2021, 70, .	0.3	0
197	Outcome-Driven Thresholds for Pulse Pressure on Office and Out-of-the-Office Blood Pressure Measurement. , 2014, , 447-457.		0
198	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. <i>Diabetes</i> , 2020, 69, 1532-P.	0.3	0

#	ARTICLE	IF	CITATIONS
199	Abstract 14182: Genome Wide Association Study for High Sensitive Cardiac Troponin T Levels Identifies a Novel Gene in Europeans With Type 1 Diabetes. <i>Circulation</i> , 2020, 142, .	1.6	0
200	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2022, 3, .	0.3	0